HIV-related Kaposi sarcoma (KS) is common in sub-Saharan Africa, but optimal treatment strategies in resource-limited settings remain unclear. We did a retrospective cohort study of adults diagnosed with KS before initiating antiretroviral therapy (ART) at three ART programs in South Africa, Malawi and Zambia. We extracted data from medical charts at HIV clinics and oncological referral centers and used electronic data from the International epidemiology Databases to Evaluate AIDS Southern Africa. We used descriptive statistics to assess tumor (T) and systemic illness (S) stage and treatment of AIDS-KS patients. Kaplan-Meier analyses were used to assess survival after KS diagnosis. We analyzed data from 57 patients in total (20 from South Africa, 20 from Zambia, 17 from Malawi). Median age at KS diagnosis was 35 years and similar across sites. The percentage of patients with poor risk AIDS-KS (T1S1) was similar in South Africa (25%) and Malawi (24%) and higher in Zambia (45%). All AIDS-KS patients initiated ART at the HIV clinic. For KS care, in South Africa 18 patients (90%) were referred to an oncology department; in Malawi and Zambia most patients were managed by the HIV clinics. In Malawi and South Africa, most AIDS-KS patients received systemic chemotherapy, in Zambia one patient received chemotherapy at the HIV clinic. A year after KS diagnosis, 15 patients (75%) in South Africa, 10 patients (50%) in Zambia, and 8 patients (47%) in Malawi were still alive; another 3 patients (15%) in South Africa, 8 patients (40%) in Zambia and 4 patients (24%) in Malawi were lost to follow-up. Management of AIDS-KS patients varied considerably across sites in Malawi, South Africa and Zambia. We need more reliable survival data for AIDS-KS patients in sub-Saharan Africa before we can assess which treatments and clinical pathways should be adopted in a specific setting.
Introduction
Kaposi sarcoma (KS) is a common HIV-related malignancy in subSaharan Africa (SSA) [1] . While HIV treatment programs have expanded massively over the past decade, resources for oncological care are still very limited in most SSA countries [1] . A recent Cochrane review [2] suggested that, in general, patients with severe HIV-related KS might benefit from a combination of antiretroviral therapy (ART) and chemotherapy; however, optimal management strategies for AIDS-KS patients in resource-limited settings remain unclear. We compared clinical stage, clinical management and outcomes of adult AIDS-KS patients enrolled in ART programs in Malawi, South Africa, and Zambia.
Methods
In this retrospective cohort study we included adult (aged ≥16 system [3] . T and S stages were extracted from charts, if available, and otherwise derived from documented information. T0S0, T0S1 and T1S0 were considered good risk and T1S1 poor risk. CD4 cell count at KS diagnosis was the measurement closest to KS diagnosis (-180/+7 days). Patient and tumor characteristics at baseline and treatments received were analyzed descriptively. Results are presented in percentages, medians and interquartile ranges (IQR).
We used Kaplan-Meier analyses to estimate survival after KS diagnosis. Patients were defined as lost to follow-up (LTFU) if there was no contact for ≥6 months prior to the data extraction date.
Patients LTFU were censored at last contact date. In additional analyses we combined patients who died with those LTFU. Analyses were done in Stata 13.1 (StataCorp LP).
Results
We extracted data for 60 AIDS-KS patients. Three Malawian patients were ineligible; 57 patients were included in the analysis. All patients were diagnosed with AIDS-KS before initiating ART at the HIV clinic. Two KS cases (10%) in South Africa and none in Malawi and Zambia were histologically confirmed. In Malawi and Zambia, most AIDS-KS patients were male; in South Africa, 60% (N = 12) were female (Table 1) South Africa, 84% (50%-96%) in Zambia and 66% (36%-84%) in Malawi ( Figure 1 ). When we included LTFU as a failure event, oneyear survival probabilities dropped to 75% (95% CI 50%-89%) in South Africa, 50% (95% CI 27%-69%) in Zambia, and 47% (95% CI 23%-68%) in Malawi.
Discussion
For this international comparison, we deliberately identified patients at HIV clinics and followed their path through the health care system. We extracted data from charts of HIV clinics and oncology departments. The retrospective design ensured that we captured routine conditions, and that our study had no effect on clinical [5, 6] . In Malawi, all patients received chemotherapy, as described in a previous Lighthouse Trust study [7] .
We found that 90% of patients from Khayelitsha (Cape Town) received chemotherapy, while an earlier study reported that only 29% received chemotherapy [5] . This difference is likely due to improved service delivery over time. To our knowledge, published data on routine KS treatment at ART programs in Zambia are not available. Our one-year survival estimate from Lighthouse Trust was lower than a recent estimate from a specialized KS clinic in Malawi [6] , perhaps because different chemotherapy regimens were used, and perhaps because more specialized oncological care was available at the KS clinic. Our survival estimate for South Africa was in line with a previous study [8] . Another study from Khayelitsha However, our and other studies have shown that in SAA, patients are still diagnosed in advanced KS stages [5, 6] . In addition to HIV treatment, KS patients are likely to benefit from specialized oncology care. However, data from SSA are scarce and findings from high-income countries cannot be extrapolated to African settings. Survival after KS diagnosis is an essential measure to assess and compare treatment outcomes in AIDS-KS patients.
However, survival data are prone to bias if LTFU is substantial [9] .
AIDS-KS patients are more likely to be LTFU than HIV-positive patients without KS [10] , so these patients might require dedicated tracking efforts to obtain reliable survival estimates.
Conclusion
Despite increasing ART availability, many patients are still diagnosed 
